eCORE
- Advanced Therapies and Advanced Interventions, Nanomedicine, Transplant & Donation
- Personalized Medicine, Innovative Diagnostics, Molecular Imaging & Digital Health
Team
Group Leader
Maria Queralt Gorgas Torner, Marta Miarons Font
Principal Investigator (PI)
Maria Queralt Gorgas Torner, Marta Miarons Font, David Berlana Martín, José Bruno Montoro Ronsano
Researchers
Carla Alonso Martínez, Danae Anguita Domingo, Angel Arévalo Bernabé, Maria Josep Cabañas Poy, Maria Josep Carreras Soler, Susana Clemente Bautista, José Manuel del Río Gutiérrez, Laura Doménech Moral, Héctor Carlos García Diaz, Laura Gómez Ganda, Javier Gómez Alonso, Maria Rosa Gómez Domingo, Ariadna Gracia Moya, Maria Blanca Guembe Zabaleta, María Guerra Gonzalez, Inés Jiménez Lozano, Juan Carlos Juárez Giménez, Patricia Marrero Álvarez, María Eugenia Palacio Lacambra, Alba Pau Parra, Adrián Puertas Sanjuan, Berta Renedo Miró, Javier Santander Reboreda, Maria del Carmen Torres Moreno, Emili Vallvé Alcón, Pau Vancells Lujan, Jana Vidal Otero
PhD Students
Ignasi Cardona Pascual, Sonia García García, María Larrosa García, Carlos Javier Parramón Teixidó, Javier Varela González-Aller
Selected Publications
Villa S, Escrihuela-Vidal F, Fernández-Hidalgo N, Escudero-Sánchez R, Cabezón I, Boix-Palop L, Díaz-Pollán B, Goikoetxea AJ, García-País MJ, Pérez-Rodríguez MT, Crespo Á, Buzón-Martín L, Sanz-Peláez O, Ramos-Merino L, Fiorante S, Muñoz P; Ceftaroline MRSA Group Spain GEIRAS-SEIMC (Campany D et al)
Ceftaroline for bloodstream infections caused by methicillin-resistant Staphylococcus aureus: a multicentre retrospective cohort study
Clin Microbiol Infect. 2024 Nov 23:S1198-743X(24)00551-2
DOI: 10.1016/j.cmi.2024.11.022
IF: 10.9
Rodríguez-Pombo L, Gallego-Fernández C, Jørgensen AK, Parramon-Teixidó CJ, Cañete-Ramirez C, Cabañas-Poy MJ, Basit AW, Alvarez-Lorenzo C, Goyanes A
3D printed personalized therapies for pediatric patients affected by adrenal insufficiency
Expert Opin Drug Deliv. 2024 Nov;21(11):1665-1681
DOI: 10.1080/17425247.2024.2399706
IF: 5.0
Clemente Bautista S, Segarra Cantón Ó, Padullés-Zamora N, García García S, Álvarez Beltrán M, Larrosa García M, Cabañas Poy MJ, Sanz-Martínez MT, Vázquez A, Gorgas Torner MQ, Miarons M
Long-Term Effectiveness and Safety of Proactive Therapeutic Drug Monitoring of Infliximab in Paediatric Inflammatory Bowel Disease: A Real-World Study
Pharmaceutics. 2024 Dec 10;16(12):1577
DOI: 10.3390/pharmaceutics16121577
IF: 4.9
Berlana D, Albertos R, Barquin R, Pau-Parra A, Díez-Poch M, López-Martínez R, Cea C, Cantenys-Molina S, Ferrer-Costa R
Impact of Omega-3 Fatty Acid Supplementation in Parenteral Nutrition on Inflammatory Markers and Clinical Outcomes in Critically Ill COVID-19 Patients: A Randomized Controlled Trial
Nutrients. 2024 Sep 10;16(18):3046
DOI: 10.3390/nu16183046
IF: 4.8
Carreras MJ, Renedo-Miró B, Valdivia C, Tomás-Guillén E, Farriols A, Mañós L, Vidal J, Alcalde M, De la Paz I, Jiménez-Lozano I, Palacio-Lacambra ME, Sabaté N, Felip E, Garralda E, Garau M, Gorgas MQ, Monterde J, Tabernero J
Drug Cost Avoidance Resulting from Participation in Clinical Trials: A 10-Year Retrospective Analysis of Cancer Patients with Solid Tumors
Cancers (Basel). 2024 Apr 17;16(8):1529
DOI: 10.3390/cancers16081529
IF: 4.5
Selected Projects
Screening and Linkage to Hepatitis C Care in Patients Attended at the Outpatient Unit of the Pharmacy Service in a Tertiary Hospital in Spain
Principal Investigator: Jana Vidal Otero
Agency: AbbVie Spain, S.L.U.
Funding: 15,000 €
Period: 2023-2025
Association Between Phytosterol Content in Parenteral Nutrition and the Development of Liver Damage Linked to Parenteral Nutrition
Principal Investigator: David Berlana Martín
Agency: Sociedad Española de Farmacia Hospitalaria (SEFH)
Funding: No funding
Period: 2023-2025
Real-World Observational Safety Study of Tedizolid: Evaluation of the Incidence of Serotonergic Syndrome and Other Adverse Effects
Principal Investigator: Alba Pau Parra, David Campany Herrero
Agency: None
Funding: No funding
Period: 2017-2025
Observational, Open, Retrospective, Multicenter Study to Evaluate the Safety and Effectiveness of Recombinant FVIII Factor Lonoctocog Alfa (Afstyla®) in a Population of Patients with Moderate and Mild Hemophilia A Undergoing Surgery
Principal Investigator: Juan Carlos Juárez Giménez
Agency: None
Funding: No funding
Period: 2022-2024
Environmental Impact of Inhaler Therapies in a Cystic Fibrosis Unit: Sustainable Strategies
Principal Investigator: Laura Gómez Ganda
Agency: None
Funding: No funding
Period: 2023-2024
Selected Dissemination Activities
LXVI Congress of the Spanish Society of Hematology and Hemotherapy [LXVI Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia]
Place: Palma de Mallorca
Date: 01/01/1970
Brief: A member of our research team, C. Alonso, presented an oral communication on the feasibility of administering lymphodepleting chemotherapy to patients receiving CAR-T therapy in our day hospital, eliminating the need for hospital admission.
MORE INFO
Hot Topic Day “Pediatric Medications in 2024, Availability and Perspectives”
Place: Elysées Biarritz 22-24 rue Quentin Bochart (Paris)
Date: 11/07/2024
Brief: C.J. Parramón participated in a conference to present his PhD project on 3D printing for personalized pediatric treatment.
MORE INFO
XXV Pediatric Pharmacy Course [XXV Curs de Farmàcia Pediàtrica]
Place: Vall d’Hebron Barcelona Hospital Campus (Barcelona)
Date: 01/01/1970
Brief: The Maternal and Pediatric Pharmacy Service organized the annual Pediatric Pharmacy course, emphasizing the unique characteristics of pediatric patients and explaining why they cannot be treated as small adults.
MORE INFO
I Course on Pharmacogenetics and Pharmacogenomics: Precision Personalized Medicine [I Curso de Farmacogenética y Farmacogenómica: Medicina Personalizada de Precisión]
Place: Online-Hospital Universitari Vall d'Hebron (Barcelona)
Date: 01/01/1970
Brief: This course, aimed at healthcare professionals and directed by M.Q. Gorgas, M. Miarons, S. García and M. Larrosa, has been designed by an exceptional team of multidisciplinary experts to thoroughly review basic concepts of pharmacology and genetics, and to address the challenges of implementing Pharmacogenetics in the Spanish healthcare system as well as in Research and Technological Advances.
MORE INFO
XI Oncology Therapy Course for Hospital Pharmacists [XI Curso de Terapia Oncológica para Farmacéuticos de Hospital]
Place: Spanish Society of Hospital Pharmacists. Madrid
Date: 01/01/1970
Brief: The Spanish Society of Hospital Pharmacists (SEFH) and its Oncological Pharmacy Group (GEDEFO) organize one of the most significant projects twice a year, under the leadership of researcher M.J. Carreras. This initiative focuses on training and updating hospital pharmacists in oncological pharmacotherapy, enhancing their clinical approach and integrating them into the multidisciplinary cancer care team. It includes training for obtaining accreditation in Oncological Pharmacy (Board Certified Oncology Pharmacists, BCOP) by the American Board of Pharmaceutical Specialties (BPS).
MORE INFO
